Stay updated on Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial
Sign up to get notified when there's something new on the Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial page.

Latest updates to the Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial page
- Check4 days agoChange DetectedThe Study Details page appears unchanged between the two screenshots; no new or removed information was detected.SummaryDifference0.5%

- Check11 days agoNo Change Detected
- Check32 days agoChange DetectedMajor update: announces a funding-related operating status notice and a new version v3.2.0; replaces the earlier v3.1.0 release.SummaryDifference3%

- Check39 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0. The change is limited to the revision label; no core content or critical data appears to be altered.SummaryDifference0.1%

- Check54 days agoChange DetectedUpdated from Revision: v3.0.1 to Revision: v3.0.2; the 'Back to Top' link was removed.SummaryDifference0.2%

- Check61 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. Additionally, a 'Back to Top' feature has been added for improved navigation.SummaryDifference0.2%

- Check68 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location, as well as the introduction of new medical terms related to renal cell carcinoma and pembrolizumab. However, many related topics and previous location details have been removed.SummaryDifference2%

Stay in the know with updates to Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial page.